Researchers have discovered a promising development that could potentially make CAR T-cell therapy more effective in the treatment of solid tumours. CAR T-cell therapy is an innovative treatment in which a patient's immune cells are modified to attack cancer cells. Until now, this method has worked particularly well for blood cancers such as leukaemia, but it has been difficult to combat solid tumours.
An important obstacle is that solid tumours have a complex environment that makes it difficult for the modified cells to do their job. Scientists are therefore focusing on specific proteins on the cell surface of tumour cells. A striking candidate is uPAR, a protein that is more prevalent on diseased and ageing cells, and also on cells surrounding tumours.
By engineering CAR T-cells to target uPAR, these cells are better able to attack the tumour and surrounding harmful cells. This opens up new possibilities for treating solid tumours where this therapy was previously not effective enough. Although this approach is still being researched further, initial results show that it is a valuable step forward.
This is important news for people who want to live longer and stay healthy. Innovations such as this could contribute in the future to better treatments for cancer, a disease that becomes more common as we age.
Source: Reason
